This segment focuses on developing cell-based immunotherapies, primarily utilizing the Sleeping Beauty transposon system for non-viral genetic modification of T cells. Research and development efforts are directed towards engineering T cells to express T cell receptors (TCRs) or chimeric antigen receptors (CARs) that target specific cancer antigens. The goal is to create personalized cell therapies that can effectively recognize and eliminate tumor cells. This involves preclinical studies, clinical trials, and optimization of manufacturing processes to enhance T cell potency and persistence. The therapeutic areas covered include solid tumors and hematologic malignancies, with the aim of improving patient outcomes and providing durable remissions. Partnerships with institutions like MD Anderson Cancer Center are crucial for advancing this segment.

This segment centers on the development of Ad-RTS-hIL-12 plus veledimex, a gene delivery system designed to regulate the production of IL-12, a master regulator of the immune system. The technology aims to focus the patient's immune system to attack cancer cells in a controlled manner. Research and development activities involve optimizing the gene delivery system, understanding the mechanisms of IL-12-mediated anti-tumor responses, and conducting clinical trials to evaluate the safety and efficacy of the approach. The primary therapeutic area is recurrent glioblastoma multiforme (rGBM) in adults, with the potential to expand to other cancer types. The goal is to provide a targeted and effective immunotherapy option for patients with limited treatment options. Regulatory and clinical aspects are critical, with ongoing efforts to demonstrate clinical benefit and secure regulatory approvals.